Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo.

To investigate the role of neutrophils in the efficacy of photodynamic therapy (PDT) in rhabdomyosarcoma-bearing rats, the number of these circulating phagocytes was decreased or increased before interstitial PDT by use of rabbit anti-rat neutrophil serum or granulocyte colony-stimulating factor, respectively. After administration of the antiserum, the number of circulating neutrophils decreased by 99.9%. However, the number of monocytes, lymphocytes, and platelets decreased as well (by 100%, 80%, and 25%, respectively). Under these conditions, PDT did not retard tumor growth at all. However, after cessation of the antiserum treatment 5 days after PDT, a striking decrease in the growth rate occurred subsequent to an increase above the normal range of the number of circulating neutrophils. Administration of the granulocyte colony-stimulating factor led to a specific 4-fold increase in the number of circulating neutrophils. In these rats, the tumor growth at day 2 after PDT was retarded as compared with PDT-treated rats that received saline only. Statistical evaluation of both experimental conditions showed that the efficacy of PDT, expressed as the percentage of change in tumor volume at day 2 after treatment, was dependent on the number of circulating neutrophils present at the day of PDT (P = 0.001; r2 = 0.482). Apparently, neutrophils are indispensable for successful PDT in vivo.

[1]  T. Mang,et al.  Effect of photodynamic therapy on blood flow in normal and tumor vessels. , 1988, Surgery.

[2]  B W Henderson,et al.  Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice. , 1988, Cancer research.

[3]  D. Faulds,et al.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. , 1994, Drugs.

[4]  H. Reinhold.  Quantitative evaluation of the radiosensitivity of cells of a transplantable rhabdomyosarcoma in the rat. , 1966, European journal of cancer.

[5]  J. Moan,et al.  The mechanism of photodynamic inactivation of human cells in vitro in the presence of haematoporphyrin. , 1979, British Journal of Cancer.

[6]  B W Henderson,et al.  Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. , 1987, Cancer research.

[7]  W. Star,et al.  Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. , 1986, Cancer research.

[8]  J. Dipersio,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil activation. , 1992, Blood reviews.

[9]  M T Tseng,et al.  The effect of photodynamic therapy on the microcirculation. , 1988, The Journal of surgical research.

[10]  W. Star,et al.  Effect of photodynamic therapy on the endothelium-dependent relaxation of isolated rat aortas. , 1993, Cancer research.

[11]  M. Korbelik,et al.  Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). , 1994, Cancer letters.

[12]  T J Dougherty,et al.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. , 1976, Cancer research.

[13]  W. Siegert,et al.  Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation , 1994, The Lancet.

[14]  G. Kuhnle,et al.  Effects of photodynamic therapy on leucocyte-endothelium interaction: differences between normal and tumour tissue. , 1995, British Journal of Cancer.

[15]  W. Star,et al.  Tumor and normal tissue response to interstitial photodynamic therapy of the rat R-1 rhabdomyosarcoma. , 1992, International journal of radiation oncology, biology, physics.

[16]  T. Wieman,et al.  Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. , 1990, Cancer research.

[17]  S. Britton,et al.  Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. , 1984, Cancer research.

[18]  T. Dougherty,et al.  Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. , 1981, Cancer research.

[19]  B. Sallerfors.  Endogenous production and peripheral blood levels of granulocyte-macrophage (GM-) and granulocyte (G-) colony-stimulating factors. , 1994, Leukemia & lymphoma.

[20]  W. Sluiter,et al.  Photodynamic treatment of human endothelial cells promotes the adherence of neutrophils in vitro. , 1996, British Journal of Cancer.

[21]  T. Dougherty,et al.  HOW DOES PHOTODYNAMIC THERAPY WORK? , 1992, Photochemistry and photobiology.

[22]  A. D. Hoyes,et al.  Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. , 1986, British Journal of Cancer.

[23]  M. Korbelik,et al.  Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. , 1995, British Journal of Cancer.

[24]  C J Gomer,et al.  Differential cell photosensitivity following porphyrin photodynamic therapy. , 1988, Cancer research.

[25]  D. Bellnier.  Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factors-α , 1991 .

[26]  D. Metcalf,et al.  The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells , 1989, Nature.

[27]  T. Mang,et al.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. , 1985, Cancer research.

[28]  M. Dewhirst,et al.  Diminished leukocyte-endothelium interaction in tumor microvessels. , 1992, Cancer research.

[29]  J. Spikes.  PORPHYRINS AND RELATED COMPOUNDS AS PHOTODYNAMIC SENSITIZERS * , 1975, Annals of the New York Academy of Sciences.

[30]  P B Cerrito,et al.  The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. , 1992, Cancer Research.